General Catalyst-backed Transcarent to acquire Accolade for $621m.

General Catalyst-backed Transcarent, a health and care experience company, agreed to acquire Accolade, an innovative healthcare company, for $621m. “Joining forces with Transcarent allows us to expand our mission of empowering people to make the best decisions for their health and wellbeing. The two companies share a focus on embracing AI and advanced technology to change the way consumers experience the healthcare system. Combining Transcarent’s complex care experience with Accolade’s people and 16 years of healthcare data, we will create a more personalized healthcare experience for people while improving outcomes and driving down costs,” Rajeev Singh, Accolade Chief Executive Officer.